Gene expression profiling in breast cancer

American Journal of Translational Research

Volumn 5, Issue 2, 2013, Pages 132-138

  Arango, Belisario A ^a   Rivera, Celine L ^a   Glück, Stefan ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Early breast cancer; Gene profiling; Predictive and prognostic power

Indexed keywords

ANTHRACYCLINE; ANTIESTROGEN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CELL PROLIFERATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HIGH RISK POPULATION; HUMAN; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT OUTCOME;

EID: 84875773003     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Polychemotherapy for early breast cancer: an overview of the randomized trials. Early breast cancer trialists' collaborative group. Lancet 1998; 352: 930-942.
3. Tamoxifen for early breast cancer: an overview of the randomized trials. Early breast cancer trialists' collaborative group. Lancet 1998; 351: 1451-1467.
4. Goldhirsch A, Wood C, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert concensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
5. National comprehensive cancer network (NCCN). Clinical practice guideline in oncology. Breast cancer version 3.2012.
6. Mook S, Scmidt MK, Rutgers EJ, Van de Velde AO, Visser O, Rutgers SM, Armstrong N, Van't veer LJ, Ravdin PM. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! Program: a hospital-based retrospective cohort study. Lancet Oncol 2009; 11: 1070-1076.
7. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St. Gallen international expert concensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 8: 1319-1329.
8. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 3: 207-219.
9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
10. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Early breast cancer trialists' collaborative group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet 2011; 378: 771-784.
11. Gluck S, Mamounas T. Improving outcomes in early stage breast cancer. Oncology 2010; 24: 1-15.
12. Nkoy FL, Hammond ME, Rees W, Belnap T, Rowley B, Catmull S, Sause W. Variable specimen handling affects hormone receptor test results in women with breast cancer: a large multihospital retrospective study. Archipathol lab med 2010; 134: 606-612.
13. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG-98. J Clin Oncol 2007; 25: 3846-3852.
14. Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL. Standarization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 2011; 29: 2978-2984.
15. Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin breast cancer 2006; 7: 153-157.
16. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG. Tamoxifen and chemotherapy for lymph-node negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-1682.
17. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8: R25.
18. Van de Vijer MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
19. Espinosa E, Vara JA, Redondo A, Sanchez JJ, Hardisson D, Zamora P, Pastrana FG, Cejas P, Martinez B, Suarez A, Calero F, Baron MG. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol 2005; 23: 7278-7285.
20. Buyse M, Loi S, van't Veer LJ, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ; TRANSBIG Consortium. Validation and clinical utitlity of a 70-gene prognostic signature for women with node negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192.
21. Cardoso F, Van'tveer LJ, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile. The MINDACT trial. J ClinOncol 2008; 26: 729-735.
22. Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijer MJ, Rutgers EJ, Vrancken Peeters MJ, van Tinteren H, Van't veer LJ, Rodenhuis S. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010; 119: 551-558.
23. Gluck S, De Snoo F, Peeters J, Somlo G, Storks-Sloots L, van't Veer LJ. Response and long term outcomes after neoadjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtypyingby MammaPrint and BluePrint. J Clin Oncol 2012; Abst 10597.
24. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smads J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijer MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-272.
25. Toussaint J, Sieuwerts AM, Haibe-Kains B, Desmedt C, Rouas G, Harris AL, Larsimont D, Piccart M, Foekens JA, Durbecq V, Sotiriou C. Improvements of the clinical applicability of the genomic grade index through a qrt-pcr test performed on froze and formalin-fixed paraffin-embedded tissues. BMC Genomics 2009; 10: 424-436.
26. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679.
27. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains F, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotirou C; TRANSBIG consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007; 13: 3207-3214.
28. Glück S, Ross JS, Royce M, McKenna EF Jr, Perou CM, Avisar E, Wu L. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treatment 2012; 3: 781-791. DOI: 10.1007/s10549-011-1412-7.
29. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222-5232.
30. Gluck S, Yip AY, Ng EL. Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer? Expert opinion 2012; 16: S17-S22.